Long-Term Academic Performance Following Prenatal Opioid Analgesic Exposure: A Population-Based Risk Assessment

Highlights

• Prenatal exposure to common prescription opioids like codeine and oxycodone is associated with negligible effects on third-grade reading and numeracy scores.
• A significant clinical signal was identified for tramadol exposure, which was linked to a larger decrease in academic performance compared to other opioid monotherapies.
• The overall observed effect size for most opioids (adjusted mean difference -0.05) falls below the conventional threshold for a small effect (Cohen’s d = 0.2), suggesting limited clinical impact at the population level.
• Future research must focus on whether the tramadol-specific outcomes reflect true neurobiological interference or unmeasured confounding related to maternal health status.

Background

The management of pain during pregnancy presents a significant clinical challenge. While the risks of neonatal abstinence syndrome (NAS) associated with illicit opioid use or long-term medication for opioid use disorder (MOUD) are well-documented, the long-term neurodevelopmental impact of intermittent or short-term prescription opioid analgesics—such as codeine, oxycodone, and tramadol—is less clearly defined. As these medications are frequently prescribed for acute or chronic pain in the obstetric population, understanding their impact on the progeny’s cognitive and academic trajectory is paramount for evidence-based counseling and health policy.

Historically, concerns have been raised regarding the potential for opioids to interfere with early brain development, specifically through interaction with endogenous opioid systems involved in neuronal proliferation and migration. However, separating the effects of the drug from the underlying maternal condition (pain, stress, or socioeconomic factors) has been a methodological hurdle for most observational studies.

Key Content

Population-Based Evidence on Academic Outcomes

Recent evidence from a large-scale population-based cohort study in New South Wales, Australia (Varney et al., 2026), provides a robust analysis of this association. The study utilized linked data from birth records, pharmaceutical dispensing databases, and national standardized test results (NAPLAN) for over 85,000 children born between 2003 and 2011.

Approximately 10.2% of the children in this cohort were exposed to at least one prescription opioid in utero, with codeine being the most prevalent agent. The primary outcomes were Z-scores in third-grade reading and numeracy. The investigators utilized linear mixed-effects models with propensity score weighting to account for a wide array of maternal and school-level confounders.

Evidence by Therapeutic Class: Codeine, Oxycodone, and Tramadol

The synthesis of data reveals a nuanced picture when stratified by the type of opioid monotherapy:

• Any Opioid Exposure: Children exposed to any opioid analgesic showed a slight decrease in reading and numeracy scores (adjusted mean difference [aβ] -0.05, 95% CI -0.06 to -0.03). This effect size is statistically significant due to the large sample size but is considered below the threshold for clinical or educational significance.
• Codeine and Oxycodone: The results for these common analgesics mirrored the overall cohort findings, suggesting that their use in pregnancy does not result in meaningful academic impairment by age 8 or 9.
• Tramadol: In contrast, exposure to tramadol was associated with a more pronounced deficit. The aβ for reading was -0.25 (95% CI -0.31 to -0.18) and for numeracy was -0.22 (95% CI -0.29 to -0.16). This represents a distinct deviation from the safety profile of other weak-to-moderate opioids.

Methodological Advances and Confounding

One of the strengths of recent research in this domain is the move toward propensity score weighting and clustering adjustments. By comparing children of women who were dispensed opioids with those who were not, while adjusting for maternal age, socioeconomic status, and school environment, researchers have narrowed the gap between correlation and causation. However, the ‘tramadol signal’ remains controversial. Critics argue that tramadol may be prescribed for specific types of pain (e.g., neuropathic or chronic) that might be associated with different maternal comorbidities than those treated with codeine, potentially introducing unmeasured confounding.

Translational Implications and Post-natal Support

While the direct pharmacological impact of most opioids appears minimal, the broader context of maternal wellbeing remains a critical factor in child development. Emerging evidence on parenting interventions (e.g., the SFSC programme in England) suggests that family-based support can significantly improve parental mental wellbeing in diverse populations (PMID: 41887826). Implementing such evidence-based support systems for mothers requiring complex pain management during pregnancy may mitigate secondary risks to child development, regardless of the analgesic chosen.

Expert Commentary

From a clinical perspective, the Varney et al. study is reassuring for the use of codeine and oxycodone when clinically indicated. The data suggests that for the vast majority of pregnant women requiring acute pain relief, these agents do not pose a substantial threat to the child’s future academic success.

However, the tramadol findings warrant a ‘pause for thought.’ Tramadol’s mechanism is unique; it acts both as a mu-opioid receptor agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI). This dual action could theoretically alter fetal neurodevelopment differently than pure opioids. The academic deficit observed (aβ -0.25) approaches a level that might be noticed in a classroom setting, although it still remains within the ‘small effect’ range.

Clinicians should also consider the ‘Healthy China 2030’ or similar global health blueprints that emphasize early screening and prevention (PMID: 41864235). While that framework focuses on stroke and adult health, the principle of life-course health—starting from the prenatal period—is applicable here. If certain prenatal exposures are identified as risk markers, they should trigger early educational monitoring for the child.

Limitations of the current evidence include the lack of data on paternal factors, maternal smoking status (which is often poorly recorded), and the precise duration of opioid use beyond dispensing records. Furthermore, the reliance on third-grade testing (age 8–9) may not capture later-emerging cognitive deficits or behavioral issues that manifest in adolescence.

Conclusion

In summary, the most comprehensive data to date indicates that prenatal exposure to standard prescription opioid analgesics, such as codeine and oxycodone, does not significantly impair third-grade academic performance. These findings support the cautious, short-term use of these agents when non-opioid alternatives are insufficient. The outlier status of tramadol, however, suggests a need for clinical vigilance and further investigation into its specific neurodevelopmental effects. Moving forward, the integration of prenatal pharmacological data with post-natal parenting support and early childhood educational monitoring will be essential to optimizing outcomes for this vulnerable population.

References

• Varney B, Zoega H, Gillies MB, Bruno C, Havard A, Shand A, Nassar N, Brett J. Prenatal Prescription Opioid Analgesic Exposure and Academic Performance in Third Grade Children: A Population-Based Cohort Study. BJOG. 2026;133(4):[In Press]. PMID: 41834337.
• Harpole V, et al. Effectiveness and cost-effectiveness of a parenting programme to improve family wellbeing in England (TOGETHER): a multicentre, single-blind, randomised controlled trial. Lancet Public Health. 2026;11(4):e233-e244. PMID: 41887826.
• Wang Y, et al. Stroke in China: advances in prevention and management on the path to a healthy China. Lancet Neurol. 2026;25(4):379-395. PMID: 41864235.